Introduction
============

In Latin America, it is estimated that 1.8 million people are living with human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome (AIDS). Despite 100,000 new HIV infections having been diagnosed in 2017, the HIV incidence decreased 13.7% between 2000 and 2017 ([@B55]). In Brazil, HIV prevalence among the general population is below 0.6% and it is estimated that AIDS cases among Brazilians reached 882,810 by June 2017 ([@B10]). HIV prevalence is higher in key populations at risk, for example 17.5% in men who have sex with men (MSM) ([@B34]). The detection rate of AIDS has been falling steadily in Brazil in recent years. However, the Central Western region showed little change in its detection rate in the last 10 years, reaching 16.7 cases per 100 thousand inhabitants in 2016 ([@B10]).

Universal access to combined antiretroviral therapy (cART) in Brazil was crucial in order to increase survival and decrease AIDS-related hospitalizations in HIV-1 infected individuals ([@B51]). Although, the development of drug resistance mutations is a significant obstacle to maintaining HIV-1 replication suppression and can lead to viral load increase and consequently transmission of viruses with drug resistance mutations. Therefore, transmitted drug resistance mutations (TDRM) have become an important challenge, since they have been described for all drugs used in the clinical management of HIV and as incidence and prevalence vary by region this highlights the importance of its monitoring. The prevalence of TDRM could vary according to the study population, methods and lists of resistance mutations used to calculate these rates ([@B8]).

Brazil has an extensive border, covering about 15,000 km, exhibiting great socioeconomic and cultural diversity across regions. Concerning HIV-1 subtypes, subtype B is the most prevalent, followed by F1, and BF1 recombinants in most Brazilian regions ([@B19]; [@B45]; [@B42]; [@B30]), except for the Southern region, where subtype C is highly prevalent ([@B50]; [@B17]; [@B27]). However, even in the same geographic region, the HIV-1 distribution could be heterogeneous ([@B28]). In border areas, intense drug trafficking and prostitution occur; both situations may affect local epidemic dynamics. Taking these geographical and epidemiological characteristics together into consideration, the study of HIV-1 genetic diversity and transmission networks as well as drug resistance mutations in this region is relevant.

Materials and Methods {#s1}
=====================

Subjects and Study Design
-------------------------

We conducted a cross-sectional survey among antiretroviral naïve HIV-infected individuals recruited in Campo Grande, the capital of Mato Grosso do Sul (MS) State, from 2011 to 2014. One hundred and seventy-two individuals were enrolled at Reference Centers for Parasitic and Infectious Diseases ([@B25]), and thirty-two were MSM recruited in a cross-sectional study ([@B24]). Inclusion criteria were: (a) having confirmed diagnosis for HIV-1; (b) being over 18 years old; (c) being antiretroviral naïve; (d) having signed the informed consent form in earlier surveys, which predicted storage of samples and their utilization in future research; and (e) having sample stored in sufficient quantity to perform the analyses proposed. Following these criteria, 190 individuals were selected for the subsequent analysis. This study was carried out in accordance with the recommendations of the Ethical Committee on Human Research of the Federal University of Mato Grosso do Sul, that is in accordance with the Declaration of Helsinki. The protocol was approved by under protocol number 1151451, CAAE 46185915.8.0000.0021.

Amplification of HIV-1 PR/RT Region
-----------------------------------

DNA was extracted from 200 μL of each whole blood sample by using the QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The partial *polymerase* (*pol*) gene including protease/reverse transcriptase (PR/RT) region was amplified by nested polymerase chain reaction (PCR) using combinations of primers described elsewhere ([@B20]). The amplified products were analyzed by electrophoresis using agarose gels (1%). Amplicons were purified using the Illustra GFX^®^ PCR DNA and Gel Band Purification Kit (GE Healthcare, United Kingdom), following the manufacturer's recommendations. The purified DNA was sequenced using Big Dye Terminator Cycle Sequencing Ready Reaction kit v.3.1 (Applied Biosystems, CA, United States) and processed with an automated ABI 3130xl sequencer (Applied Biosystems), using Sanger's method.

Sequence Analysis
-----------------

The sequences were edited in DNASTAR software and then aligned with reference sequences from Los Alamos HIV Sequence Database^[1](#fn01){ref-type="fn"}^ using the Clustal W program implemented in MEGA 6.0 software ([@B54]). All sequences are available in GenBank (accession number [MF545192](MF545192)-[MF545340](MF545340)). The final PR/RT alignment covered a fragment of 1261 bp, corresponding to nucleotides 2254 to 3514 relative to the HXB2 genome.

Maximum Likelihood (ML) phylogenetic was constructed with the PhyML 3.0 program using an online web server ([@B31]). The Smart Model Selection recommended the GTR+I+G nucleotide substitution model to be used in the ML ([@B35]). The heuristic tree search was performed using the SPR branch-swapping algorithm, and the branch support was calculated with the approximate likelihood-ratio (aLRT) SH-like test ([@B3]). Recombinant profiles were inferred by bootscan analyses with a sliding window of 300 bp, steps of 10 bp and Kimura-2 parameters model using SimPlot 3.5.1 software ([@B38]).

Those sequences that clustered together with high aLRT support (\>0.90) in the ML tree were analyzed for the occurrence of possible transmission clusters. Therefore, such sequences were submitted to analysis using nucleotide Basic Local Alignment Search Tool (BLASTn) ([@B2]) to recover reference sequences with high similarity (\>95%). These sequences retrieved were added to three new alignments from pure subtypes (B, D, and F1), and a new ML tree was obtained to verify the maintenance of the transmission clusters according to their subtypes. For subtypes D and F1 analyses we included all available Brazilian reference sequences, however, duplicate sequences were removed. For subtype B, at least ten representative sequences from each Brazilian State and all sequences from Mato Grosso do Sul state available at the Los Alamos HIV Sequence Database were included. Before performing the phylogenetic analyses to confirm the transmission clusters, drug-resistance mutations positions were stripped from each alignment, resulting in a fragment of 891 bp from nucleotides 2262 to 3251 relative to HXB2 genome. Our final cluster classification was defined based on aLRT (\>90) in the phylogenetic analyses ([Figure 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}), and low mean pairwise genetic distances (≤4.5) of clustered sequences have been employed.

Genotypic Analysis of HIV-1 Drug Resistance
-------------------------------------------

To investigate the presence of TDRM, the sequences were submitted to Stanford HIV Database for Transmitted DRM \[TDRM/Calibrated Population Resistance Tool (CPR Tool)\] Version 6.0 ([@B26]), which uses the mutation list according to [@B5].

Statistical Analysis
--------------------

Statistical analyses were conducted using the SPSS 17.0 statistical analysis software package (SPSS Inc., Chicago, IL, United States). Median, standard deviation (SD), range and frequencies (%) were used to describe patients' characteristics. The frequency of TDRMs was also calculated, and the chi-square or Fisher exact test was employed when appropriate. A *p* value of \< 0.05 was defined as statistically significant.

Results
=======

Out of 190 antiretroviral naïve patients who had samples available for DNA extraction, 172 were PR/RT amplified (90.5%), and from them 150 (87.2%) were successfully sequenced. From those 150 studied subjects, 62.0% were male, with an average age of 36 years, ranging from 18 to 70 years. More than half of participants were white (53.3%), heterosexual (64.0%), and reported less than 12 years of schooling (80.7%), and irregular condom use (54%). Only 6.7% of them were sex workers. Sociodemographic and behavioral characteristics are listed in [Table 1](#T1){ref-type="table"}. No statistically significant correlation was detected between the variables presented in [Table 1](#T1){ref-type="table"} and HIV-1 subtypes.

###### 

Sociodemographic and behavioral characteristics of 150 cART-naïve subjects according to the HIV-1 most frequent subtypes, Central Brazil.

  Variable                                              N     (%)      Subtype B   Sub-subtype F1   Subtype C
  ----------------------------------------------------- ----- -------- ----------- ---------------- -----------
  **Gender**                                                                                        
  Male                                                  93    (62.0)   64 (63.4)   10 (66.7)        7 (58.3)
  Female                                                57    (38.0)   37 (36.6)   5 (33.3)         5 (41.7)
  Age (years)                                                                                       
  18--29                                                49    (32.7)   33 (32.7)   3 (20.0)         6 (50.0)
  30--39                                                51    (34.0)   36 (35.6)   8 (53.3)         2 (16.7)
  40 or more                                            50    (33.3)   32 (31.7)   4 (26.7)         4 (33.3)
  **Skin color/ethnicity**                                                                          
  White                                                 80    (53.3)   57 (56.4)   8 (53.3)         6 (50.0)
  Non-white                                             70    (46.7)   44 (43.6)   7 (46.7)         6 (50.0)
  **Educational (years)**                                                                           
  0                                                     4     (2.7)    3 (3.0)     0 (0.0)          0 (0.0)
  1--12                                                 117   (78.0)   79 (78.2)   11 (73.3)        9 (75.0)
  ≥12                                                   29    (19.3)   19 (18.8)   4 (26.7)         3 (25.0)
  **Monthly income**                                                                                
  \<2 minimum wages                                     20    (13.3)   11 (10.9)   1 (6.7)          2 (16.7)
  2--5 minimum wages                                    97    (64.7)   65 (64.3)   12 (80.0)        6 (50.0)
  \>5 minimum wages                                     31    (20.7)   24 (23.7)   2 (13.3)         4 (33.3)
  Missing                                               2     (1.3)    1 (0.1)     0 (0.0)          0 (0.0)
  **Frequency of alcohol consumption**                                                              
  None                                                  92    (60.9)   63 (62.4)   8 (53.3)         7 (58.3)
  Weekly                                                51    (35.1)   34 (33.7)   6 (40.0)         3 (25.0)
  Daily                                                 7     (4.0)    4 (3.9)     1 (6.7)          2 (16.7)
  **Illicit drug use**                                                                              
  No                                                    118   (78.7)   80 (79.2)   11 (73.3)        8 (66.7)
  Yes, no injecting drugs                               28    (18.6)   18 (17.8)   3 (20.0)         4 (33.3)
  Yes, injecting drugs                                  4     (2.7)    3 (3.0)     1 (6.7)          0 (0.0)
  Sexual orientation                                                                                
  Heterosexual, female                                  57    (38.0)   37 (36.6)   5 (33.3)         5 (41.7)
  Heterosexual, male                                    39    (26.0)   27 (26.8)   3 (20.0)         3 (25.0)
  MSM                                                   54    (36.0)   37 (36.6)   7 (46.7)         4 (33.3)
  **Number of sexual partners in the last 12 months**                                               
  0                                                     13    (8.7)    6 (5.9)     2 (13.2)         1 (8.3)
  1                                                     77    (51.3)   53 (52.5)   7 (46.7)         6 (50.0)
  2--5                                                  40    (26.7)   28 (27.7)   4 (26.7)         4 (33.4)
  6--10                                                 4     (2.7)    3 (3.0)     1 (6.7)          0 (0.0)
  \>10                                                  16    (10.6)   11 (10.9)   1 (6.7)          1 (8.3)
  **Use of condoms in the last 12 months**                                                          
  Always                                                69    (46.0)   51 (50.5)   6 (40.0)         6 (50.0)
  Occasionally/Never                                    81    (54.0)   50 (49.5)   9 (60.0)         6 (50.0)
  **Presence of TDRM**                                                                              
  Yes                                                   18    (12.0)   14 (13.9)   0 (0.0)          2 (16.7)
  No                                                    132   (88.0)   87 (86.1)   15 (100)         10 (83.3)
                                                                                                    

MSM, men who have sex with men; TDRM, transmitted drug resistance mutations.

Phylogenetical analyses revealed that 101 sequences (67.3%) were classified as subtype B, 15 (10%) as F1, 12 (8%) as C, two (1.3%) as subtype D and 20 (13.3%) possible recombinants ([Figure 1](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"}). The phylogenetic and bootscan analysis of these twenty sequences revealed that four (2.7%) were CRF28_29BF, three (2.0%) were CRF31_BC, one (0.7%) was CRF60_BC, and 12 (8.0%) were unique recombinant forms (URF) ([Figure 2B](#F2){ref-type="fig"}).

![Map of Brazil indicating Brazilian regions and MS State, from which HIV-1 sequences were obtained. The pie chart shows HIV-1 subtypes distribution based on *pol* sequences included in this study.](fmicb-10-00020-g001){#F1}

![ML phylogenetic tree of 150 HIV-1 PR/RT sequences from Mato Grosso do Sul, Central-West Brazil. The analyzed PR/RT alignment covered a fragment of 1261 bp, corresponding to nucleotides 2254 to 3514 relative to HXB2 genome. Reference sequences retrieved from GenBank are not labeled. ALRT values are represented only if greater \> 0.90. Possible HIV-1 transmission clusters were indicated by numbers. HET = sample obtained from heterosexual individual; HSH = sample obtained from men who have sex with men. **(A)** Pure HIV-1 subtypes and **(B)** Recombinant sequences.](fmicb-10-00020-g002){#F2}

TDRM to at least one class of antiretroviral drug was found in 18 sequences (12%), and the drug resistance mutation to nucleoside reverse transcriptase inhibitor (NRTI) was the most common (12/150; 8%), followed by non-nucleoside reverse transcriptase inhibitor (NNRTI) (7/150; 4.7%) and PI resistance (3/150; 2%) ([Table 2](#T2){ref-type="table"}). Of these, twelve (8%) were singleton mutations and six (4.0%) multiple. K103N was the most frequent resistance mutation observed (5/150; 3.3%) followed by V75M (4/150; 2.7%). There was no statistical difference between sexual orientation and the prevalence of TDRM and HIV-1 subtypes distribution.

###### 

Characteristics of the 18 cART-naïve subjects with TDRM.

  ID       Age/Gender   Resistance mutations   HIV-1 Subtype   Co-infection             
  -------- ------------ ---------------------- --------------- ------------------ ----- -------------------------------------
  HET080   50/F         --                     V106M           --                 BF1   Lifetime syphilis^a^
  HET116   23/M         --                     K103N           M46I               B     
  HSH187   31/M         V75M                   --              N88D               B     Lifetime syphilis^a^
  HSH430   40/M         L210W, T215D           --              --                 B     Hepatitis B^b^
  HET446   31/F         --                     V106M           --                 B     --
  HET463   19/M         --                     K103N           --                 D     --
  HSH502   27/M         D67N, K219Q            --              --                 C     Lifetime syphilis^a^
  HET510   40/F         M41L, T215D            --              M46I, V82T, L90M   B     --
  HET521   26/F         K70R                   --              --                 B     --
  HET545   40/M         --                     K103N           --                 B     Lifetime syphilis^a^ Hepatitis B^b^
  HET573   37/F         V75M                   --              --                 B     --
  HSH595   28/M         V75M                   --              --                 B     Hepatitis B^b^
  HET607   32/M         V75M                   --              --                 B     --
  HET809   29/M         F77L                   --              --                 C     --
  HET810   31/F         T215S                  --              --                 B     --
  HSH851   21/M         L210W                  --              --                 B     --
  HSH876   27/M         --                     K103N           --                 B     Lifetime syphilis^a^ Hepatitis B^b^
  HSH878   22/M         M184V                  K103N, P225H    --                 B     Lifetime syphilis^a^
                                                                                        

HET, sample obtained from heterosexual individual; HSH, sample obtained from men who have sex with men; ID, sample identification; NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitor; NRTI, Nucleoside Reverse Transcriptase Inhibitor; PI, Protease inhibitor.

a

Lifetime syphilis: anti-

Treponema pallidum

positivity in ELISA.

b

Hepatitis B: anti-HBc total and/or HBsAg seroposivity in ELISA.

Twenty-four possible transmission clusters, including 57 individuals were identified according to the adopted criteria (aLRT \> 90 in ML analysis). The clusters involved from two to five individuals and seventeen of them belong to HIV-1 subtype B, one to subtype D, three to sub-subtype F1 ([Figure 2A](#F2){ref-type="fig"}) and three were recombinant forms being 2 BF1 and 1 BD ([Figure 2B](#F2){ref-type="fig"}). The inclusion of a huge number of reference sequences enabled reinvestigation by ML of the transmission clusters, in combination with the criteria of presenting high aLRT support and low mean genetic distance, allowed us to depict twenty previously identified possible transmission clusters from pure HIV-1 subtypes B, D, and F1. The possible transmission clusters 1c, 3, 10, and 21 were not confirmed. Some of the originally detected clusters remained with the same configuration (2,8,11,13,16, and 18); meanwhile, some of them presented a new shape. In the Cluster numbers (1, 4, 5, 9, 15, 17, 19, and 20) some Brazilian reference sequences clustered together to ours. We also verified that some sequences were excluded from the original possible clusters (1, 3, 6, 9, 10, 12, and 14). The possible clusters 1 and 6 give rise to two new transmission clusters (1a,b and 6a,b). The original possible clusters ([Figure 2A,B](#F2){ref-type="fig"}) and the confirmed transmission clusters ([Figure 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}) were summarized in [Table 3](#T3){ref-type="table"}. Since the clusters BD (22) and BF1 (23 and 24) were unique recombinant forms, we did not perform an additional ML phylogenetic tree.

![ML phylogenetic tree highlighting HIV-1 subtype B transmission clusters. The confirmed HIV-1 transmission clusters were highlighted in green and numbered according to the previous grouping from [Figure 1](#F1){ref-type="fig"}. All clusters present aLRT ≥ 0.90 and low mean pairwise genetic distances (≤4.5). The analysis involved 520 HIV-1 B PR/RT sequences (102 sequences from the present study, 331 Brazilian reference sequences, 82 non-Brazilian reference sequences, and 5 HIV-1 Subtype C sequences as outgroup). The analyzed fragment corresponds to 891 bp (2262 to 3251 nt relative to HXB2 genome) and drug-resistance mutations positions were stripped.](fmicb-10-00020-g003){#F3}

![ML phylogenetic tree showing the transmission clusters among HIV-1 subtypes of D and F1 sequences. The confirmed HIV-1 transmission clusters were highlighted in green and numbered according to the previous grouping from [Figure 1](#F1){ref-type="fig"}. All clusters present aLRT ≥ 0.90 and low mean pairwise genetic distances (≤4.5). The sub-subtype F1 analysis involved 493 PR/RT sequences (15 sequences from the present study, 467 Brazilian reference sequences, 6 non-Brazilian reference sequences, and 5 HIV-1 Subtype C sequences as outgroup). From subtype D analysis, 94 sequences were used as follows: 2 detected in the present study, 17 HIV-1 Brazilian reference sequences, 72 non-Brazilian reference sequences and HIV-1 Subtype C sequences as outgroup).](fmicb-10-00020-g004){#F4}

###### 

Cluster confirmation of cART-naïve HIV-1 sequences according to aLRT and genetic distance.

  [Figure 2](#F2){ref-type="fig"}       [Figure 3](#F3){ref-type="fig"}       Transmission cluster confirmation                                                                                  
  ------------------------------------- ------------------------------------- --------------------------------------- -------------- -------------------- --------------- ---------------------- ---------------
  **Subtype HIV-1 B**                                                                                                                                                                            
  HSH645                                1                                     0.98                                    HSH645         1a                   0.99            1.8                    Confirmed
  HSH684                                                                                                              HSH684                                                                     
  HSH876                                                                                                              BRMS57                                                                     
  HSH878                                                                                                              HSH878         1b                   0.93                                   Confirmed
  HSH543                                                                                                              HSH876                                              3.5                    
  HET220                                                                                                              BRMS171                                                                    
  HET673                                                                                                              HSH543         1c                   0.9             6.0                    Not confirmed
  HET075                                                                                                              HET220                                                                     
                                                                                                                      HET673         not confirmed                                               
                                                                                                                      HET075         not confirmed                                               
  HET141                                2                                     0.95                                    HET141         2                    0.94                                   Confirmed
  HET642                                                                                                              HET642                                              4.2                    
  HET737                                                                                                              HET737                                                                     
  HET362                                3                                     0.91                                    HET362         3                    0.93            5.8                    Not confirmed
  HET622                                                                                                              HET622                                                                     
  HET219                                                                                                              HET219         not confirmed                                               
  HSH187                                4                                     0.93                                    HSH187         4                    0.95            3.4                    Confirmed
  HSH595                                                                                                              HSH595                                                                     
  HET607                                                                                                              BRMS58                                                                     
                                                                                                                      BRMS14_10                                                                  
                                                                                                                      HET607                                                                     
  HSH152                                5                                     1                                       HSH152         5                    1                                      Confirmed
  HSH430                                                                                                              HSH430                                              3.9                    
                                                                                                                      BRMS40                                                                     
  HSH408                                6                                     0.92                                    HSH408         6a                   1               1.3                    Confirmed
  HSH862                                                                                                              HSH862                                                                     
  HSH871                                                                                                              HSH871         6b                   0.99            1.4                    
  HET850                                                                                                              BRMS97                                                                     Confirmed
                                                                                                                      BRMS99                                                                     
                                                                                                                      HET850         not confirmed                                               
  HET671                                7                                     1                                       HET671         7                    1               2.6                    Confirmed
  HET438                                                                                                              HET438                                                                     
  HET517                                8                                     1                                       HET517         8                    1               3.9                    
  HET797                                                                                                              HET797                                                                     Confirmed
  HSH703                                                                                                              HSH703                                                                     
  HET562                                9                                     0.93                                    HET562         9                    0.96            3.6                    
  HET188                                                                                                              BRMS55                                                                     Confirmed
                                                                                                                      BRMS05                                                                     
                                                                                                                      HET188         not confirmed                                               
  HSH143                                10                                    0.93                                    HSH143         not confirmed        Not confirmed                          
  HET437                                                                                                              HET437         not confirmed                                               
  HSH239                                11                                    0.92                                    HSH239         11                   0.95                                   Confirmed
  HSH066                                                                                                              HSH066                                              4.4                    
  HET694                                                                                                              HET694                                                                     
  HSH881                                12                                    0.96                                    HSH881         12                   0.93            3.3                    Confirmed
  HET249                                                                                                              HET249                                                                     
  HET814                                                                                                              HET814         not confirmed                                               
  HSH874                                                                                                              HSH874         not confirmed                                               
  HET367                                                                                                              HET367         not confirmed                                               
  HET757                                13                                    1                                       HET757         13                   1               1.3                    
  HSH867                                                                                                              HSH867                                                                     
  HSH875                                                                                                              HSH875                                                                     Confirmed
  HSH716                                                                                                              HSH716                                                                     
  HSH717                                                                                                              HSH717                                                                     
  HSH53                                 14                                    0.98                                    HSH53          14                   0.99            1.9                    Confirmed
  HSH94                                                                                                               HSH94                                                                      
  HSH240                                                                                                              HSH240         not confirmed                                               
  HET111                                15                                    0.98                                    HET111         15                   0.96            3.6                    
  HSH109                                                                                                              HSH109                                                                     Confirmed
                                                                                                                      MS34                                                                       
  HET38                                 16                                    0.98                                    HET38          16                   0.94            3.7                    Confirmed
  HET510                                                                                                              HET510                                                                     
  HET462                                17                                    1                                       HET462         17                   0.98            3.4                    Confirmed
  HET631                                                                                                              HET631                                                                     
  HET801                                                                                                              HET801                                                                     
                                                                                                                      MS02                                                                       
                                                                                                                      MS46                                                                       
                                                                                                                                                                                                 
  **[Figure 2](#F2){ref-type="fig"}**   **[Figure 4](#F4){ref-type="fig"}**   **Transmission cluster confirmation**                                                                              
                                                                                                                                                                                                 
  **Sequence**                          **Cluster number**                    **aLRT**                                **Sequence**   **Cluster number**   **aLRT**        **Genetic distance**   
                                                                                                                                                                                                 
  **Subtype D**                                                                                                                                                                                  
  HET463                                18                                    1                                       HET463         18                   1               3.4                    Confirmed
  HSH761                                                                                                              HSH761                                                                     
  **Sub-subtype F1**                                                                                                                                                                             
  HSH006                                19                                    1                                       HSH006         19                   0.97            4.0                    Confirmed
  HSH264                                                                                                              HSH264                                                                     
  HSH265                                                                                                              HSH265                                                                     
  HSH387                                                                                                              HSH387                                                                     
  HSH534                                                                                                              HSH534                                                                     
                                                                                                                      BR07SP153                                                                  
                                                                                                                                                                                                 
                                                                                                                                                                                                 
  HET256                                20                                    0.99                                    HET256         20                   1               3.6                    Confirmed
  HET318                                                                                                              HET318                                                                     
  HET361                                                                                                              HET361                                                                     
                                                                                                                      BRMS38                                                                     
                                                                                                                                                                                                 
                                                                                                                                                                                                 
  HET140                                21                                    0.92                                    HET140         21                   1               4.8                    Not confirmed
  HSH739                                                                                                              HSH739                                                                     
  HET796                                                                                                              HET796                                                                     
                                                                                                                      BRGO4074                                                                   
                                                                                                                      BRGO6051                                                                   
  **Recombinant BD**                                                                                                                                                                             
  HET45                                 22                                    1                                                                                                                  
  HET46                                                                                                                                                                                          
  **Recombinant BF**                                                                                                                                                                             
  HET643                                23                                    1                                                                                                                  
  HET122                                                                                                                                                                                         
  HET483                                                                                                                                                                                         
  HET793                                24                                    0.99                                                                                                               
  HET353                                                                                                                                                                                         
                                                                                                                                                                                                 

HET: sample obtained from heterosexual individual; HSH: sample obtained from men who have sex with men.

All subtype B sequences were classified as pandemic B. Among subtype B confirmed clusters, twelve (12/17; 70.6%) had more than two sequences, and five (5/17; 29.4%) were composed of two sequences. Five clusters comprised MSM samples of this study with or without other Brazilian sequences (clusters 1a, 1b, 5, 6a, and 14), four with HET samples (clusters 2, 7, 16, and 17), six, mixed HET, and MSM sequences (clusters 4, 8, 11, 12, 13, and 15). Two clusters (6b and 9) were formed by one sequence from our study and two other Brazilian sequences from MS state, retrieved from Genbank ([Table 3](#T3){ref-type="table"}).

Individuals from ten clusters of subtype B were positive for lifetime syphilis and/or Hepatitis B and C infections. Four (4/17; 23.5%) contained sequences with TDRM, and two of them (clusters 1b and 4) were composed by MSM sharing the same TDRM. Cluster 1b included two MSM who had a history of Treponema pallidum infection and K103N mutation, and one of them reported being a sex worker and bisexual. Cluster 4 grouped two sequences from MSM (HSH187 and HSH595), one from a male HET, and sequences BRMS58 and BRMS14_10, both from males ([@B16]), all of them had the V75M substitution, associated with resistance to NRTI inhibitors.

Samples belonging to non-B subtypes were grouped into three clusters ([Figure 4](#F4){ref-type="fig"}). Two of them (19 and 20), belonging to F1 subtype, contained more than two samples. The cluster 19 contained five sequences from MSM, three of which reported the use of illicit drugs and two were positive for syphilis (anti-*T. pallidum*). Additionally, cluster 19 also grouped a sequence from São Paulo ([@B11]). The two samples characterized as subtype D clustered together (cluster 18).

Discussion
==========

This phylogenetic study combined detailed clinical and epidemiological data, providing valuable data for surveillance, which allowed the monitoring of HIV-1 variants, TDRM, and associations between sociodemographic characteristics and behavioral sexual groups. It is noteworthy that the study subjects were antiretroviral naïve, and therefore, they were not in virologic suppression at the time of sample collection. This fact, associated with unprotected sexual practices, a multiplicity of sexual partners and a history of sexually transmitted infections (STIs), may be crucial for the maintenance of high HIV transmission rates.

In this study, HIV-1 B subtype was identified in 67.3% of the isolates, followed by recombinant forms, subtypes F1, C, and D. This distribution reflects that found in most Brazilian regions ([@B16]; [@B18]). The frequency of 13.3% (95% CI: 7.9 to 18.8%) of recombinant forms found in this study was similar to that found in previous studies conducted in Central Brazil (16.3% and 14.5%) ([@B53]; [@B16]). The absence of the Caribbean non-pandemic subtype B (B~CAR~) differs from the previous study by [@B22], where a frequency of 5.5% from B~CAR~ were detected in Mato Grosso do Sul. Previous studies conducted in a southern region of Brazil identified differences in the distribution of subtypes according to sex and exposure category ([@B19]; [@B21]). The present study is the first conducted in MS addressing this issue, and the lack of association herein can be justified by the high frequency of bisexual behavior (33.9%) reported by homosexual individuals from our cohort, suggesting that the differential transmission of subtypes according to the exposure category is not restricted to the MSM.

In the present study, an intermediate prevalence (12.0%) of TDRM was found, according to the WHO classification ([@B5]), which is higher than that found in Northern Brazil (1.0%) ([@B23]) and is consistent with those found in previous Brazilian studies using similar sequencing technologies (6.8% to 17.2%) ([@B12]; [@B19]; [@B14]; [@B52]; [@B1]; [@B47]; [@B4]). Recently, among crack cocaine users in Central Brazil, a high prevalence of TDRM was found (58.3%). It is worth noting that only 12 HIV-positive individuals were investigated ([@B15]).

Recently, one study using massive parallel sequences of Brazilian blood donors found an overall prevalence of TDRM in PR and RT regions of the HIV-1 *pol* gene of 44.5% ([@B46]). Insufficient data to evaluate the time of HIV-1 infection and conventional sequencing usage may have caused an underestimation of TDRM prevalence ([@B44]; [@B32]; [@B43]). Besides, it has been reported that significant inequalities in access to treatment persists in Brazil, resulting in different impacts on mortality in some groups, such as non-white individuals, or those with poor formal education ([@B37]).

It is remarkable that 4.0% of virus isolates obtained in this study had multiple mutations that may further influence the response to treatment. K103N, the most frequent resistance mutation observed, is commonly related to decreased susceptibility to efavirenz and nevirapine and the V75M mutation was associated with lamivudine and/or stavudine use (NNRTI). Some studies point out that genotyping tests before initiation of cART for all patients could be cost-effective in Brazil ([@B49]; [@B39]). However, these tests are still available only to specific populations, such as serodiscordant partners and HIV infected pregnant women.

Although HIV prevalence among MSM increased beyond expectations in Brazil, no difference between TDRM prevalence in homosexuals and heterosexuals was observed in this study. This result may reflect trends of feminization and the increase in heterosexual transmissions observed in Brazil ([@B10]). In contrast, ([@B6]) found higher TDRM prevalence in MSM (21.4%) recruited in Brazil by respondent-driven sampling, a particular sampling technique for hard-to-reach populations. As a result, transmission networks of resistance variants may have been selected among these MSM, thus reflecting this prevalence. Due to the higher prevalence of HIV infection in MSM ([@B34]) and transgender women in Brazil ([@B29]), pre-exposure prophylaxis is recommended by the Brazilian Ministry of Health, who have made efforts to implement it and suggest it may be cost-effective ([@B40]).

Transmission clusters are frequently defined by low genetic distance (1.0%-4.5%) within cluster sequences and high support phylogenetic clusters ([@B36]; [@B7]), herein employing both resources we were able to determine nineteen transmission clusters. However, more recently, transmission network approaches have also been used to this purpose, such as HIV clustering ([@B56]), Cluster picker and Cluster Matcher ([@B48]).

Seventeen transmission clusters were confirmed among subtype B isolates, some of them grouped patients with co-infections. Further evidence suggests that unprotected sexual intercourse and the presence of STIs that cause ulcerative lesions such as syphilis play important roles as cofactors in HIV transmission ([@B41]; [@B33]). This emphasizes the importance of prevention and treatment interventions.

Preventive actions regarding HIV-1 transmission are needed to disrupt the network and to reduce the spread of TDRM, since 29.4% of the clusters (5/17) contained samples with TDRM. Two of these groups were sharing the same substitution, showing the possibility of transmission of resistance between these individuals. Therefore, since 2013 the Brazilian Health Ministry recommendation, following the WHO recommendation, established that all HIV infected individuals should start the treatment to accomplish viral suppression, this being an effective way to reduce the HIV transmission ([@B9]).

Clusters containing sequences from individuals with different sexual behaviors, including homosexual and bisexual contacts, were found in HIV-1 B (clusters 4, 8,11,12, 13, and 15) and D subtypes (cluster 18). Thus, factors such as being a sex worker, having multiple sexual partners, inconsistent condom use, and bisexual behavior may increase exposure to resistant HIV-1 isolates, both in heterosexual and homosexual networks.

The detection of clusters containing Brazilian samples from previous studies in Central-Western and Southeastern Brazil ([@B11]; [@B13]; [@B16]) can be explained by the high mobility of the population, reinforcing the possibility of the spreading of infection despite great geographic distances, thus influencing local dynamics of diseases. Therefore, transmission networks and potential links with the different exposure categories should be further investigated in Brazil.

The study has some limitations. We interviewed all individuals face-to-face; consequently, risk behaviors may have been under-reported, leading to potential underestimation of associations with these variables and TDRM prevalence. Moreover, due to the study design, sample composition may not be representative of Campo Grande-MS epidemic and the absence of time of HIV-1 infection or diagnosis can portray an older epidemic. Even using a very limited number (1.4% from the total number of AIDS cases in Mato Grosso do Sul) of HIV-1 sequences from Mato Grosso do Sul, we were able to detect transmission clusters. However, we could not obtain detailed epidemiological information about the sequences from other Brazilian studies that were in some clusters. On the other hand, these findings enhance the understanding of the HIV-1 genetic characteristics, transmitted drug resistance, and transmission networks, as the research comprises not only individuals with epidemiological features in common but also the spread of strains between homosexuals and heterosexuals.

We highlight the urgent need for increased transmission monitoring of antiretroviral-resistant isolates, aiming for the selection of more effective therapeutic regimens, viral suppression, and hence the interruption of HIV-1 transmission networks. Improved understandings of risks, including potential linkages between sexual exposures among MSM, may contribute to designing preventive interventions and for improving HIV surveillance regarding TDRM in the largest country in Latin America.
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